Saltar al contenido
Merck

Influenza virus-host interactome screen as a platform for antiviral drug development.

Cell host & microbe (2014-12-04)
Tokiko Watanabe, Eiryo Kawakami, Jason E Shoemaker, Tiago J S Lopes, Yukiko Matsuoka, Yuriko Tomita, Hiroko Kozuka-Hata, Takeo Gorai, Tomoko Kuwahara, Eiji Takeda, Atsushi Nagata, Ryo Takano, Maki Kiso, Makoto Yamashita, Yuko Sakai-Tagawa, Hiroaki Katsura, Naoki Nonaka, Hiroko Fujii, Ken Fujii, Yukihiko Sugita, Takeshi Noda, Hideo Goto, Satoshi Fukuyama, Shinji Watanabe, Gabriele Neumann, Masaaki Oyama, Hiroaki Kitano, Yoshihiro Kawaoka
RESUMEN

Host factors required for viral replication are ideal drug targets because they are less likely than viral proteins to mutate under drug-mediated selective pressure. Although genome-wide screens have identified host proteins involved in influenza virus replication, limited mechanistic understanding of how these factors affect influenza has hindered potential drug development. We conducted a systematic analysis to identify and validate host factors that associate with influenza virus proteins and affect viral replication. After identifying over 1,000 host factors that coimmunoprecipitate with specific viral proteins, we generated a network of virus-host protein interactions based on the stage of the viral life cycle affected upon host factor downregulation. Using compounds that inhibit these host factors, we validated several proteins, notably Golgi-specific brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1) and JAK1, as potential antiviral drug targets. Thus, virus-host interactome screens are powerful strategies to identify targetable host factors and guide antiviral drug development.

MATERIALES
Product Number
Marca
Descripción del producto

Sigma-Aldrich
ANTI-FLAG® M2 monoclonal antibody produced in mouse, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)